A Trial Investigating the Pharmacokinetic Properties of Five Formulations of Fast-acting Insulin Aspart 200 U/mL in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2019
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Apr 2019 Status changed from recruiting to completed.
- 08 Nov 2018 New trial record
- 29 Oct 2018 Status changed from not yet recruiting to recruiting.